{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:23Z","timestamp":1792887803222,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.nmd.2021.12.005","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T11:54:55Z","timestamp":1641297295000},"page":"185-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0063","authenticated-orcid":false,"given":"Maria","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Papaliagkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Notas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Chatzikyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Zafeiridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Papagiannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-2651","authenticated-orcid":false,"given":"Marianthi","family":"Arnaoutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios K.","family":"Kimiskidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.12.005_bib0001","series-title":"ed. gene reviews((r))","article-title":"Spinal muscular atrophy","author":"Prior","year":"1993"},{"key":"10.1016\/j.nmd.2021.12.005_bib0002","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0003","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0004","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0006","doi-asserted-by":"crossref","first-page":"e60113","DOI":"10.1371\/journal.pone.0060113","article-title":"SMA-MAP: a plasma protein panel for spinal muscular atrophy","volume":"8","author":"Kobayashi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0007","doi-asserted-by":"crossref","first-page":"e35462","DOI":"10.1371\/journal.pone.0035462","article-title":"Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study","volume":"7","author":"Finkel","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0008","first-page":"293","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.nmd.2021.12.005_bib0009","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ejhg.2012.233","article-title":"Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study","volume":"21","author":"Tiziano","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2021.12.005_bib0010","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","author":"Annoussamy","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0012","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.12.005_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-150081","article-title":"Spinal muscular atrophy biomarker measurements from blood samples in a clinical trial of valproic acid in ambulatory adults","volume":"2","author":"Renusch","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.12.005_bib0014","doi-asserted-by":"crossref","unstructured":"Elsheikh B., King W., Peng J., Swoboda K.J. Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy. 2020;61:187\u201391.","DOI":"10.1002\/mus.26756"},{"key":"10.1016\/j.nmd.2021.12.005_bib0015","doi-asserted-by":"crossref","unstructured":"Wijngaarde C.A., Stam M. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. 2020.","DOI":"10.1212\/WNL.0000000000010540"},{"key":"10.1016\/j.nmd.2021.12.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2021.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.12.005_bib0018","first-page":"A109","article-title":"Onasemnogene abeparvovec gene-replacement therapy for spinal muscular atrophy: from bench to bedside","volume":"74","author":"Kaufmann","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.nmd.2021.12.005_bib0019","article-title":"Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0021","doi-asserted-by":"crossref","first-page":"e4473","DOI":"10.1002\/nbm.4473","article-title":"Quantification of disease progression in spinal muscular atrophy with muscle MRI-a pilot study","author":"Otto","year":"2021","journal-title":"NMR Biomed"},{"key":"10.1016\/j.nmd.2021.12.005_bib0022","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.12.005_bib0023","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.12.005_bib0024","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/0883073811405053","article-title":"Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophy","volume":"26","author":"Sproule","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/acn3.406","article-title":"Longitudinal characterization of biomarkers for spinal muscular atrophy","volume":"4","author":"Bonati","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-10332-5","article-title":"Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study","author":"Querin","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ncn3.140","article-title":"A study of valproic acid for patients with spinal muscular atrophy","volume":"3","author":"Saito","year":"2015","journal-title":"Neurol Clin Neurosci"},{"key":"10.1016\/j.nmd.2021.12.005_bib0029","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/mus.24527","article-title":"Training improves oxidative capacity, but not function, in spinal muscular atrophy type III","volume":"52","author":"Madsen","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.12.005_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.12.005_bib0031","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0032","article-title":"Respiratory trajectories in type 2 and non-ambulant 3 Spinal muscular atrophy in the iSMAC cohort study","author":"Trucco","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.12.005_bib0033","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","author":"De Wel","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0034","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fneur.2019.00293","article-title":"ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase iia trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor Fasudil in amyotrophic lateral sclerosis","volume":"10","author":"Lingor","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0b013e318225aabf","article-title":"Multipoint incremental motor unit number estimation as an outcome measure in ALS","volume":"77","author":"Shefner","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.12.005_bib0036","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ene.14587","article-title":"Clinical and radiological profile of patients with spinal muscular atrophy type 4","volume":"28","author":"Souza","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0037","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1093\/brain\/awr229","article-title":"Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy","volume":"134","author":"Farrar","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2021.12.005_bib0038","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinph.2018.11.009","article-title":"Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy","volume":"130","author":"G\u00fcnther","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0039","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinph.2018.08.025","article-title":"The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy","volume":"129","author":"Querin","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archneurol.2011.1697","article-title":"Corticomotoneuronal integrity and adaptation in spinal muscular atrophy","volume":"69","author":"Farrar","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0041","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","article-title":"Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3","volume":"79","author":"Wadman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.12.005_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2021.12.005_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.51092","article-title":"Whole-blood dysregulation of actin-cytoskeleton pathway in adult spinal muscular atrophy patients","author":"Siranosian","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0044","article-title":"The spinal and cerebral profile of adult spinal-muscular atrophy: a multimodal imaging study","volume":"21","author":"Querin","year":"2019","journal-title":"NeuroImage: Clinical"},{"key":"10.1016\/j.nmd.2021.12.005_bib0045","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00415-020-09875-4","article-title":"Cerebellar degeneration in adult spinal muscular atrophy patients","volume":"267","author":"de Borba","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102002","article-title":"Magnetic resonance imaging of the cervical spinal cord in spinal muscular atrophy","volume":"24","author":"Stam","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.nmd.2021.12.005_bib0047","doi-asserted-by":"crossref","first-page":"E653","DOI":"10.1212\/WNL.0000000000007945","article-title":"Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy","volume":"93","author":"Kollmer","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.12.005_bib0048","article-title":"Magnetization transfer ratio - a quantitative imaging biomarker for 5q spinal muscular atrophy","author":"Kollmer","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0049","article-title":"Molecular biomarkers for spinal muscular atrophy: a systematic review","author":"Navarrete-Opazo","year":"2020","journal-title":"Neurology: Clinical Practice"},{"key":"10.1016\/j.nmd.2021.12.005_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40263-019-00606-6","article-title":"Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: a Systematic Review and Meta-Analysis","volume":"33","author":"Elshafay","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nmd.2021.12.005_bib0051","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2021.12.005_bib0052","article-title":"Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0053","article-title":"Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen","author":"Kariyawasam","year":"2020","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.nmd.2021.12.005_bib0054","article-title":"Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2021.12.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000164","article-title":"Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen","volume":"3","author":"Arnold","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.nmd.2021.12.005_bib0056","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen treatment in adults with spinal muscular atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.nmd.2021.12.005_bib0057","first-page":"11","article-title":"Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients","author":"Muschen","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.nmd.2021.12.005_bib0058","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/mus.27212","article-title":"Is cerebrospinal fluid amyloid-beta42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?","volume":"63","author":"Introna","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.12.005_bib0059","first-page":"20","article-title":"Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen","author":"Totzeck","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2021.12.005_bib0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40261-021-01071-0","article-title":"Cerebrospinal fluid and clinical profiles in adult type 2-3 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre experience","volume":"41","author":"Milella","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.nmd.2021.12.005_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/ph13110341","article-title":"Precision medicine in neurology: the inspirational paradigm of complement therapeutics","volume":"13","author":"Gavriilaki","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nmd.2021.12.005_bib0062","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul Disord"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621007410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621007410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:17Z","timestamp":1760775137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621007410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0960896621007410"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.12.005","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}